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Abstract
Several microRNAs (miRNAs) have been implicated in tumor
development based on both changes in their expression
patterns and gene structural alterations in human tumors.
However, we are only now beginning to see how miRNAs
interact with classic oncogene and tumor suppressor mech-
anisms. Several recent studies have implicated the miR-34
family of miRNAs in the p53 tumor suppressor network. The
expression of miR-34a, miR-34b, and miR-34c is robustly
induced by DNA damage and oncogenic stress in a p53-
dependent manner. When overexpressed, miR-34 leads to
apoptosis or cellular senescence, whereas reduction of miR-34
function attenuates p53-mediated cell death. These findings,
together with the fact that miR-34 is down-regulated in several
types of human cancer, show that miRNAs can affect
tumorigenesis by working within the confines of well-known
tumor suppressor pathways. [Cancer Res 2007;67(23):11099–101]
Background
p53 responds to DNA damage or deregulation of mitogenic onco-
genes through the induction of cell cycle checkpoints, apoptosis, or
cellular senescence (1, 2). Mutations in p53 are often associated with
aggressive tumor behavior and poor patient prognosis (3). The p53
tumor suppressor network has been intensively studied; however,
genetic analyses long hinted at the existence of components that
remained elusive (1, 2). For example, although p53 is clearly a
transcriptional activator, numerous reports indicated that p53 also
represses the expression of specific genes either directly or indirectly
(4). The manner in which this occurred was obscure, with both
transcriptional and posttranscriptional suppression as possible
mechanisms. In the latter case, the discovery of extensive networks
of microRNAs (miRNAs), which act through the RNA interference
pathway (RNAi), offered the possibility that p53-mediated control of
miRNA expression could allow it to act indirectly to repress target
gene expression at the posttranscriptional level.
miRNAs are small, 18- to 24-nucleotide noncoding RNAs that
regulate gene expression largely through effects on productive
translation and mRNA stability (5–7). Nascent miRNA transcripts
(pri-miRNAs) are often RNA polymerase II products, with promoters
that closely resemble those of protein-coding genes. Rather than
being exported to the cytoplasm for translation, pri-miRNAs are
processed by the microprocessor complex in the nucleus, and the
hairpin products (pre-miRNAs) are then cleaved by Dicer in the
cytoplasm to generate mature miRNA duplexes (5–7). The mature
miRNA joins RNA-induced silencing complex, which it guides to
target mRNAs by imperfect base pairing that depends mainly on the
‘‘seed,’’ sequences comprising bases 2 to 7 of the mature miRNA (6).
Increasing evidence has suggested that miRNAs are components
of oncogene and tumor suppressor pathways. Inappropriate
expression and structural alterations of miRNA genes have been
found in a variety of tumor types (8, 9), and several functional
studies have shown the oncogenic or tumor-suppressive potential
of specific miRNA families (10–13). Among these are five recent
reports that uncover miRNA components in the p53 tumor sup-
pressor network (14–18).
Key Findings
miR-34s form an evolutionarily conserved miRNA family, with
three members in vertebrate genomes (miR-34a, miR-34b, and miR-
34c) and single orthologues in invertebrate species. Initial links to
tumorigenesis emerged from Welch et al. (19) who showed that the
miR-34a gene, residing at 1p36, is often lost in human neuroblas-
toma. 1p36 deletions frequently encompass very large numbers of
genes; however, primary neuroblastomas and cell lines often showed
low miR-34a expression (19). Artificial elevation of miR-34a in these
cells inhibited proliferation and activated cell death pathways (19).
Shortly afterward, links to tumor biology solidified with the
finding that miR-34 levels correlated with p53 status. Four groups
approached the general relationship between p53 and miRNAs
using a variety of different profiling approaches and cellular
contexts. Chang et al. (15) compared miRNA profiles of p53+/+ and
p53/ HCT116 cells in response to DNA damage, whereas Raver-
Shapira et al. (17) and Tarasov et al. (18) probed miRNA levels in
lung carcinoma cells (H1299) harboring regulated p53 alleles. He
et al. (16) compared miRNA expression in a series of p53+/+ and
p53/ mouse embryo fibroblasts (MEF) bearing several different
oncogenic lesions. In addition, Bommer et al. (14) identified miR-34
family from a previously published genome-wide p53 chromatin
immunoprecipitation analysis (20). Several potentially p53-respon-
sive miRNAs emerged from these studies, but all five groups zeroed
in on the miR-34 family for further study.
There are two mir-34 loci in vertebrate genomes, one encoding
miR-34a and the other yielding both miR-34b and miR-34c from a
single primary transcript. Both genes show little conservation even
among closely related species, except in the miRNA-encoding
sequences and in short promoter proximal regions that each
contains a consensus p53-binding site (14–18). The miR-34a and
miR-34b/miR-34c loci are regulated directly by interaction of p53
with these consensus sites, as can be shown by chromatin immu-
noprecipitation (14, 16–18) and by the ability of miR-34 promoters to
drive expression of luciferase reporters in a p53-dependent manner
(14–17). The consequences of miR-34 activation may vary depending
on the cell type. In some cases, ectopic expression or delivery of
synthetic miR-34 mimetics resulted in cell cycle arrest or senescence
Requests for reprints: Gregory J. Hannon, Watson School of Biological Sciences,
Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, 1 Bungtown Road,
Cold Spring Harbor, NY 11724. Phone: 516-367-8889; Fax: 516-367-8874; E-mail:
hannon@cshl.edu.
I2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-2672
www.aacrjournals.org 11099 Cancer Res 2007; 67: (23). December 1, 2007
Review
 American Association for Cancer Research Copyright © 2007 
 on December 20, 2012cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-07-2672
(16). In other cases, the output was apoptosis, with the response
being reduced by inhibition or depletion of miR-34 (14, 17).
Achieving these different outcomes may depend on the spectrum
of miR-34 regulatory targets that are expressed in a given cell type.
A combination of bioinformatic predictions and experimental
analysis led to the notion that miR-34s control broad programs of
targets involved in cell cycle control, apoptosis, and DNA repair,
among which cyclin-dependent kinase (cdk) 4, cyclin E2, cMet, cdk6,
and bcl-2 were shown as possible candidates (14, 16).
Implications
Activation of p53 leads to diverse cellular responses, including
apoptosis, cell cycle arrest, blockade of angiogenesis, and activation
of DNA repair (1, 2). The output of the p53 pathway is determined
by the coordinated transcriptional activation of p53 target genes in
a context-dependent manner (Fig. 1). For example, p53-induced
apoptosis is dependent on the induction of not only bax (21) but
also puma and noxa (22).
The identification of the miR-34 family as p53 targets expands
the repertoire of p53-regulated genes to include small RNAs. An
important lesson to be drawn from this finding is the potential for
small RNAs to fill roles in signaling network, which have persisted
as long-standing mysteries. p53 induces growth arrest through its
activation of the cdk inhibitor p21 (2). However, studies of p21-
deficient MEFs indicated the existence of another pathway that
worked in parallel with p21 to enforce p53-dependent G1 arrest
(23, 24). Searches for protein-coding mediators of the cell cycle
effects of p53 yielded several candidates, but these mainly promote
G2 arrest (2). Notably, miR-34 can induce G1 arrest independently
of p21 in specific cell types, raising the possibility that this small
RNA may normally act in parallel with p21, filling the genetically
predicted gap in this arm of the p53 pathway (16).
With accumulating evidence revealing the importance of miRNAs
in cancer, it is now accepted that miRNAs can have tumor sup-
pressor or oncogenic activity. For example, 13q14, a chromosomal
locus deleted in >50% of B-cell chronic lymphocytic leukemias,
contains two miRNAs, miR-15 and miR-16, which suppress the
expression of bcl-2 and likely act as tumor suppressors (10). The
miR-17-92 gene, which is amplified in B-cell lymphomas and shows
altered expression in numerous tumor types, displays oncogenic
activity in a variety of models (11). Now, we see that miR-34s may at
least participate in tumor suppression as part of the p53 network.
Whether or not miR-34s are bona fide tumor suppressors in their
own right awaits further study. The mir-34a gene maps to 1p36,
a region of common loss in many human tumor types (19). In
addition, reduced miR-34a expression is a frequent feature of both
pancreatic tumors and neuroblastomas (15, 19) and reduced
miR-34b and miR-34c expression has been observed in a subset of
non–small cell lung cancers (14). In these cases, the lack of miR-34
Figure 1. miR-34 in the p53 tumor suppressor network. p53 transcriptionally activates miR-34s in response to multiple cellular stresses. miR-34s, in turn, induce
apoptosis or growth arrest by posttranscriptional repression of their target genes in a context-dependent manner. RISC, RNA-induced silencing complex.
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may not simply reflect the loss of p53 as p53 is often wild-type in
these tumors. Overall, accumulating evidence is forcing us to
remodel our notions of oncogenes and tumor suppressors to
include noncoding RNAs, and as a class, these may afford new
opportunities for diagnosis and treatment of human cancer.
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